Find out how Regeneron Pharmaceuticals’ AAAAI 2026 data could reshape allergy treatment strategies and regulatory expectations.
FDA halts Anaphylm over human factors risks. Find out what this means for non-injectable epinephrine and future anaphylaxis treatments.
Allegria Therapeutics has secured USD 5.1 million in a seed extension financing round led by ALK-Abelló, with additional participation from HighLight Capital, the Lichtsteiner Foundation, and existing backer Forty51 Ventures. The Swiss biotechnology company will use the funds to nominate its first clinical candidate and advance its portfolio of mast cell-modulating therapies for allergy and